Influence of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with HBV-related acute-on-chronic liver failure

References

• Liu J, Liang W, Jing W, et al. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ. 2019;97(3):230–238. doi: 10.2471/BLT.18.219469
   PubMed Web of Science ®Google Scholar
• Mezzano G, Juanola A, Cardenas A, et al. Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis. Gut. 2022;71(1):148–155. doi: 10.1136/gutjnl-2020-322161
   PubMed Web of Science ®Google Scholar
• Ohnishi H, Sugihara J, Moriwaki H, et al. [Acute-on-chronic liver failure]. Ryoikibetsu shokogun shirizu. 1995;7:217–219.
   Google Scholar
• Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13(4):353–390. doi: 10.1007/s12072-019-09946-3
   PubMed Web of Science ®Google Scholar
• Olson JC, Wendon JA, Kramer DJ, et al. Intensive care of the patient with cirrhosis. Hepatology. 2011;54(5):1864–1872. doi: 10.1002/hep.24622
   PubMed Web of Science ®Google Scholar
• Xue R, Duan Z, Liu H, et al. A novel dynamic model for predicting outcome in patients with hepatitis B virus related acute-on-chronic liver failure. Oncotarget. 2017;8(65):108970–108980. doi: 10.18632/oncotarget.22447
   PubMedGoogle Scholar
• Wong SW, Chan WK, Mohamed R. Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B. J Viral Hepat. 2020;27(12):1297–1305. doi: 10.1111/jvh.13361
   PubMed Web of Science ®Google Scholar
• Choi HSJ, Brouwer WP, Zanjir WMR, et al. Nonalcoholic Steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B. Hepatology. 2020;71(2):539–548. doi: 10.1002/hep.30857
   PubMed Web of Science ®Google Scholar
• Charatcharoenwitthaya P, Pongpaibul A, Kaosombatwattana U, et al. The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response. Liver Int. 2017;37(4):542–551. doi: 10.1111/liv.13271
   PubMed Web of Science ®Google Scholar
• Yip TC, Lee HW, Chan WK, et al. Asian perspective on NAFLD-associated HCC. J Hepatol. 2022;76(3):726–734. doi: 10.1016/j.jhep.2021.09.024
   PubMed Web of Science ®Google Scholar
• Lee YB, Ha Y, Chon YE, et al. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B. Clin Mol Hepatol. 2019;25(1):52–64. doi: 10.3350/cmh.2018.0040
   PubMed Web of Science ®Google Scholar
• Paik JM, Kabbara K, Eberly KE, et al. Global burden of NAFLD and chronic liver disease among adolescents and young adults. Hepatology. 2022;75(5):1204–1217. doi: 10.1002/hep.32228
   PubMed Web of Science ®Google Scholar
• EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402. doi: 10.1016/j.jhep.2015.11.004
   PubMed Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi: 10.1016/j.jhep.2020.03.039
   PubMed Web of Science ®Google Scholar
• Eslam M, El-Serag HB, Francque S, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022;19(10):638–651. doi: 10.1038/s41575-022-00635-5
   PubMed Web of Science ®Google Scholar
• Lin S, Huang J, Wang M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020;40(9):2082–2089. doi: 10.1111/liv.14548
   PubMed Web of Science ®Google Scholar
• Wang QX, Xue J, Shi MJ, et al. Association between metabolic dysfunction-associated fatty liver disease and the risk of cirrhosis in patients with chronic hepatitis B-A retrospective cohort study. Diabetes Metab Syndr Obes. 2022;15:2311–2322. doi: 10.2147/DMSO.S369824
   PubMed Web of Science ®Google Scholar
• Yun B, Ahn SH, Oh J, et al. Effect of metabolic dysfunction-associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: a nationwide study. Hepatol Res. 2022;52(12):975–984. doi: 10.1111/hepr.13830
   PubMed Web of Science ®Google Scholar
• Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61(5):1038–1047. doi: 10.1016/j.jhep.2014.06.012
   PubMed Web of Science ®Google Scholar
• Perdigoto DN, Figueiredo P, Tomé L. The role of the CLIF-C of and the 2016 MELD in prognosis of cirrhosis with and without acute-on-chronic liver failure. Ann Hepatol. 2019;18(1):48–57. doi: 10.5604/01.3001.0012.7862
   PubMed Web of Science ®Google Scholar
• Song DS, Kim TY, Kim DJ, et al. Validation of prognostic scores to predict short-term mortality in patients with acute-on-chronic liver failure. J Gastroenterol Hepatol. 2018;33(4):900–909. doi: 10.1111/jgh.13991
   PubMed Web of Science ®Google Scholar
• Li J, Liang X, Jiang J, et al. PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF. Gut. 2022;71(1):163–175. doi: 10.1136/gutjnl-2020-323395
   PubMed Web of Science ®Google Scholar
• Hernaez R, Sola E, Moreau R, et al. Acute-on-chronic liver failure: an update. Gut. 2017;66(3):541–553. doi: 10.1136/gutjnl-2016-312670
   PubMed Web of Science ®Google Scholar
• Gustot T, Fernandez J, Garcia E, et al. Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology. 2015;62(1):243–252. doi: 10.1002/hep.27849
   PubMed Web of Science ®Google Scholar
• Li J, Liang X, You S, et al. Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure. J Hepatol. 2021;75(5):1104–1115. doi: 10.1016/j.jhep.2021.05.026
   PubMed Web of Science ®Google Scholar
• Lin S, Chen J, Wang M, et al. Prognostic nomogram for acute-on-chronic hepatitis B liver failure. Oncotarget. 2017;8:109772–109782. doi: 10.18632/oncotarget.21012
   PubMedGoogle Scholar
• Gao F, Li X, Wan G, et al. Development and external validation of a prognostic nomogram for acute decompensation of chronic hepatitis B cirrhosis. BMC Gastroenterol. 2018;18(1):179. doi: 10.1186/s12876-018-0911-y
   PubMedGoogle Scholar
• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. doi: 10.1038/nrgastro.2017.109
   PubMed Web of Science ®Google Scholar
• Nguyen VH, Le MH, Cheung RC, et al. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. Clin Gastroenterol Hepatol. 2021;19(10):2172–2181.e6. doi: 10.1016/j.cgh.2021.05.029
   PubMed Web of Science ®Google Scholar
• Van Kleef LA, Choi HSJ, Brouwer WP, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep. 2021;3(5):100350. doi: 10.1016/j.jhepr.2021.100350
   PubMedGoogle Scholar
• Mak LY, Yuen MF, Seto WK. Letter regarding “A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement”. J Hepatol. 2020;73(6):1573–1574. doi: 10.1016/j.jhep.2020.07.008
   PubMed Web of Science ®Google Scholar
• Hamed AE, Elsahar M, Elwan NM, et al. Managing diabetes and liver disease association. Arab J Gastroenterol. 2018;19(4):166–179. doi: 10.1016/j.ajg.2018.08.003
   PubMed Web of Science ®Google Scholar
• Pelusi S, Petta S, Rosso C, et al. Renin-Angiotensin system inhibitors, type 2 diabetes and fibrosis progression: an observational study in patients with nonalcoholic fatty liver disease. PLoS One. 2016;11(9):e0163069. doi: 10.1371/journal.pone.0163069
   PubMed Web of Science ®Google Scholar
• Elkrief L, Chouinard P, Bendersky N, et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology. 2014;60(3):823–831. doi: 10.1002/hep.27228
   PubMed Web of Science ®Google Scholar
• Elkrief L, Rautou PE, Sarin S, et al. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver Int. 2016;36(7):936–948. doi: 10.1111/liv.13115
   PubMed Web of Science ®Google Scholar
• Quek J, Ng CH, Tang ASP, et al. Metabolic associated fatty liver disease increases the risk of systemic complications and mortality. A meta-analysis and systematic review of 12 620 736 individuals. Endocr Pract. 2022;28(7):667–672. doi: 10.1016/j.eprac.2022.03.016
   PubMed Web of Science ®Google Scholar
• Sun DQ, Jin Y, Wang TY, et al. MAFLD and risk of CKD. Metabolism. 2021;115:154433. doi: 10.1016/j.metabol.2020.154433
   PubMed Web of Science ®Google Scholar
• Targher G, Byrne CD. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol. 2017;13(5):297–310. doi: 10.1038/nrneph.2017.16
   PubMed Web of Science ®Google Scholar
• Mantovani A, Lombardi R, Cattazzo F, et al. MAFLD and CKD: an updated narrative review. Int J Mol Sci. 2022;23(13):7007. doi: 10.3390/ijms23137007
   PubMed Web of Science ®Google Scholar
• Wang TY, Wang RF, Bu ZY, et al. Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nat Rev Nephrol. 2022;18(4):259–268. doi: 10.1038/s41581-021-00519-y
   PubMed Web of Science ®Google Scholar
• Alharthi J, Gastaldelli A, Cua IH, et al. Metabolic dysfunction-associated fatty liver disease: a year in review. Curr Opin Gastroenterol. 2022;38(3):251–260. doi: 10.1097/MOG.0000000000000823
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Tsutsumi T, Nakano D, et al. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region. Clin Mol Hepatol. 2022;28(2):150–163. doi: 10.3350/cmh.2021.0310
   PubMed Web of Science ®Google Scholar